# Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

Study · id `cardio:ct-nct07032311` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07032311](<https://clinicaltrials.gov/study/NCT07032311>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07032311

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07032311. Randomized; no masking; primary purpose treatment. Start 2026-08-20 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07032311, source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)
- Planned start: 2026-08-20 (anticipated) (ClinicalTrials.gov record NCT07032311, source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT07032311, source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07032311, source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07032311, source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07032311-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
- Acronym: SIPPA-QH\_HHC-2
- Condition: Type 2 Diabetes
- Condition: Liver Disease
- Intervention (Device): Behavioral Treatment
- Lead sponsor: SIPPA Solutions INC
- Lead sponsor class: INDUSTRY
- Collaborator: New York City Health and Hospitals Corporation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ae77dcfcb159d36dfa6d4c6517d29d7bd54491162d454bb5058e1c4f7b82940b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
